Stocktoria
FENNEC PHARMACEUTICALS INC. FENC
FENNEC PHARMACEUTICALS INC. (FENC) earns a Piotroski F-score of 0/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $44.6M at a -21.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 0/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.801 |
| Retained earnings / assets | -3.252 |
| EBIT / assets | -0.089 |
| Equity / liabilities | 1.011 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| FENC | FENNEC PHARMACEUTICALS INC. | 0/9 | -4.88 | — | -6.1% |
| CHRS | Coherus Oncology, Inc. | 4/9 | — | 1.4 | +59.8% |
| EDIT | Editas Medicine, Inc. | 1/9 | — | — | +25.4% |
| VYGR | Voyager Therapeutics, Inc. | 1/9 | -1.03 | — | -49.5% |
| SGMO | SANGAMO THERAPEUTICS, INC | 2/9 | — | — | -31.6% |
| KYMR | Kymera Therapeutics, Inc. | 3/9 | 9.79 | — | -16.7% |
| PLX | Protalix BioTherapeutics, Inc. | 2/9 | -11.01 | — | -1.2% |
About FENNEC PHARMACEUTICALS INC.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FAQ
Is FENC financially healthy?
FENNEC PHARMACEUTICALS INC.'s Piotroski F-score is 0/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does FENC pay a dividend?
No, FENNEC PHARMACEUTICALS INC. does not currently pay a dividend.
How profitable is FENC?
In FY2025, FENNEC PHARMACEUTICALS INC. had a net margin of -21.8% and a return on equity of -27.5%.
What is the analyst price target for FENC?
The average Wall-Street price target for FENNEC PHARMACEUTICALS INC. is $15.67, about 32.4% above the recent price, from 6 analysts.
Is FENC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on FENNEC PHARMACEUTICALS INC.: a Piotroski F-score of 0/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.